Data regarding ceftaroline use for meticillin-resistant Staphylococcus aureus bacteraemia (MRSAB) are lacking. Here we review the outcomes of 31 patients with MRSAB treated with ceftaroline, including 9 patients with endocarditis. Clinical success was observed in 23 patients (74.2%). Adverse events associated with prolonged therapy were rare and included eosinophilic pneumonia, rash and diarrhoea. We conclude that ceftaroline can be used for MRSAB.
Keywords: Bacteraemia; Ceftaroline; Endocarditis; MRSA; Meticillin-resistant Staphylococcus aureus.
Copyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.